GRI Bio, Inc. (GRI)
(Delayed Data from NSDQ)
$1.32 USD
+0.04 (3.13%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GRI 1.32 +0.04(3.13%)
Will GRI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GRI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GRI
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
GRI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for GRI
Crude Oil Falls 1%; Meta Earnings Top Views
12 Health Care Stocks Moving In Thursday's Intraday Session
Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings
GRI Bio (GRI) Reports Promising Interim Results from Phase 2a Study on IPF